Docoh
Loading...

NBIX Neurocrine Biosciences

Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.

Company profile

Ticker
NBIX
Exchange
CEO
Kevin Gorman
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
330525145

NBIX stock data

(
)

Calendar

4 Feb 21
11 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 190.3M 190.3M 190.3M 190.3M 190.3M 190.3M
Cash burn (monthly) 79.4M (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn)
Cash used (since last report) 267.96M n/a n/a n/a n/a n/a
Cash remaining -77.66M n/a n/a n/a n/a n/a
Runway (months of cash) -1.0 n/a n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
10 Feb 21 Lloyd-Smith Malcolm Common Stock Sell Dispose S No Yes 119.9542 600 71.97K 32,510
10 Feb 21 Lloyd-Smith Malcolm Common Stock Option exercise Aquire M No No 35.99 600 21.59K 33,110
10 Feb 21 Lloyd-Smith Malcolm Common Stock Sell Dispose S No Yes 119.9573 1,100 131.95K 32,510
10 Feb 21 Lloyd-Smith Malcolm Common Stock Option exercise Aquire M No No 35.99 1,100 39.59K 33,610
10 Feb 21 Lloyd-Smith Malcolm NQSO Common Stock Option exercise Dispose M No No 35.99 1,700 61.18K 21,533
8 Feb 21 Roberts Eiry Common Stock Sell Dispose S No Yes 116.8252 1,623 189.61K 18,693
8 Feb 21 Roberts Eiry Common Stock Sell Dispose S No Yes 116.6711 740 86.34K 17,231
8 Feb 21 Roberts Eiry RSU Common Stock Grant Aquire A No No 0 7,439 0 7,439
8 Feb 21 Roberts Eiry Stock Option Common Stock Grant Aquire A No No 117.63 44,632 5.25M 44,632
8 Feb 21 Abernethy Matt Common Stock Sell Dispose S No Yes 116.8059 2,030 237.12K 14,869

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

95.1% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 392 403 -2.7%
Opened positions 63 65 -3.1%
Closed positions 74 70 +5.7%
Increased positions 139 184 -24.5%
Reduced positions 147 109 +34.9%
13F shares
Current Prev Q Change
Total value 11.94B 8.55B +39.7%
Total shares 89.34M 88.85M +0.5%
Total puts 775.2K 897K -13.6%
Total calls 328.3K 355.3K -7.6%
Total put/call ratio 2.4 2.5 -6.5%
Largest owners
Shares Value Change
JHG Janus Henderson 9.16M $878.09M +39.9%
FMR 8.36M $801.03M -4.0%
Vanguard 8.34M $799.13M +2.2%
BLK Blackrock 7M $670.74M +2.7%
TROW T. Rowe Price 6.27M $601.15M -2.3%
Capital International Investors 3.41M $327.08M -20.2%
BLVGF Bellevue 3.4M $325.57M +3.0%
STT State Street 2.48M $237.45M +8.8%
Perceptive Advisors 1.9M $182.04M +22.6%
Renaissance Technologies 1.81M $173.22M -15.9%
Largest transactions
Shares Bought/sold Change
JHG Janus Henderson 9.16M +2.61M +39.9%
Capital International Investors 3.41M -862.83K -20.2%
Citadel Advisors 1.15M +836.01K +268.4%
MCQEF Macquarie 231.54K -718.6K -75.6%
Norges Bank 707.4K +707.4K NEW
HealthCor Management 226.46K -700.61K -75.6%
IVZ Invesco 1.08M -650.33K -37.5%
Alliancebernstein 58.27K -639.91K -91.7%
BEN Franklin Resources 894.87K -635.29K -41.5%
Two Sigma Advisers 0 -430.3K EXIT

Financial report summary

?
Management Discussion
  • Product Sales, net. Net product sales were $994.1 million for 2020, $752.9 million for 2019 and $409.6 million for 2018.
  • Collaboration Revenues. Collaboration revenues reflect the achievement of certain event-based milestones, royalties earned at tiered percentage rates on any net sales of ORILISSA and ORIAHNN and license fees earned under our collaboration agreements with AbbVie and MTPC.
  • In the second quarter of 2020, we recognized a $30.0 million event-based milestone as revenue upon FDA-approval of AbbVie’s ORIAHNN for uterine fibroids. In the third quarter of 2019, we recognized a $20.0 million event-based milestone as revenue upon the FDA’s acceptance of AbbVie’s new drug application, or NDA, submission of elagolix for uterine fibroids. In the third quarter of 2018, we recognized a $40.0 million event-based milestone as revenue upon FDA-approval of AbbVie’s ORILISSA for the treatment of moderate to severe pain associated with endometriosis.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: absence, adolescent, aforementioned, Aid, allosteric, amisulpride, AMPA, anesthesiologist, anhedonia, antidepressant, bandwidth, beneficiary, benzoate, Biden, biosimilar, brivaracetam, broad, CAHtalyst, cannabidiol, cap, capacity, carbamazepine, cariprazine, cenobamate, certified, CHMP, ciraprazine, Circle, citalopram, clobazam, concept, condensed, conference, contusion, corruption, Cut, DAAO, decentralized, delinquent, destroyed, differentiated, dossier, dramatically, East, EC, economy, electrical, emotional, epidemic, EPS, estradiol, faster, field, fluoxetine, Fortune, gauge, globe, Great, harbor, heard, Hedging, highest, hindered, HITECH, home, house, IIa, image, inclusion, inclusive, Indonesia, infantile, infection, injunction, insomnia, judgement, jurisdiction, Korea, lacosamide, lamotrigine, leadership, lessening, levetiracetam, literature, lowest, Malaysia, MDD, mechanism, media, Medium, member, mental, Ministry, monthly, motivation, MRI, nationwide, nonaccrual, nonpublic, norethindrone, Northern, older, opt, ORIAHNN, ORIAHNNTM, oxcarbazepine, pandemic, paused, perampanel, phenytoin, pimavanserin, pleasure, predefined, pretax, pride, prioritization, prioritize, prioritizing, proof, properly, Propionic, proven, reacquisition, Ready, reality, recurrent, refill, regression, regularly, remitted, respiratory, robust, roluperidone, rooted, Senate, sentiment, sertraline, shutdown, simultaneously, Singapore, skilled, sleep, sought, Spike, spread, stay, stayed, strong, Subtopic, Supreme, survey, Takeda, Talent, telecommunication, temporary, terrorism, Thailand, thereof, thousand, tie, topiramate, tract, transmitted, travel, tuition, turnover, unchanged, Uncollectible, uninterrupted, unsuccessful, unwilling, usability, valproate, verbal, war, Wateridge, Wave, Welfare, workforce, workplace, younger
Removed: abatement, abdomen, ablate, adjacent, advancement, affinity, allocation, analytical, analyzed, animal, ascending, assay, attenuate, automated, avoided, bargaining, beneficial, blinking, bradykinesia, building, cancelable, cancellation, cancelled, circulating, closed, collective, commencing, complicate, composition, concurrent, conditional, constipation, convertibility, cooperation, coupled, cycle, decreasing, depot, derecognition, desirable, difficulty, disagreement, discontinued, discrete, downstream, driven, dysmenorrhea, dyspareunia, emergent, endometrial, estate, exceeded, exercisable, exploited, eye, flare, floor, forfeiture, forum, fraction, frequent, genome, grimacing, half, importantly, inhibiting, injectable, injection, intercourse, internally, ion, lacking, landlord, laparoscopic, lessee, lip, location, matrix, menorrhagia, menstruation, metoclopramide, mild, monitored, monoamine, mortgage, multitude, nigra, nonexistent, nonpeptide, occupy, outsourced, overlap, pharmacological, pool, preferred, produced, protrusion, puckering, pursing, rectal, refund, regimen, Reglan, regular, removal, rent, repealing, reserved, retired, reversible, seasoned, sexual, showing, signaling, smacking, solid, somnolence, stabilized, steadily, substantia, suffering, suite, superfamily, suppression, surgery, tenant, terminal, titrating, tongue, transient, transporter, tumor, unamortized, unbiased, urinating, urination, vaginal, vesicular, writing

Patents

GRANT
Utility
Methods for the administration of certain VMAT2 inhibitors
23 Mar 21
Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-a-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is also being administered a strong cytochrome P450 3A4 (CYP3A4) inhibitor.
GRANT
Utility
Methods for the administration of certain VMAT2 inhibitors
9 Mar 21
Provided is a method of administering a vesicular monoamine transporter 2 (VMAT2) inhibitor to a subject in need thereof, wherein the subject has severe renal impairment.
GRANT
Utility
Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
9 Mar 21
Inventors: Graham Beaton, Mi Chen, Timothy Richard Coon, Todd Ewing, Wanlong Jiang, Willy Moree, Martin Rowbottom, Warren Wade, Liren Zhao, Richard Lowe, Nicole Smith, Neil Ashweek, Yun-Fei Zhu
APP
Utility
Methods for the Administration of Certain VMAT2 Inhibitors
25 Feb 21
Provided is a method of administering a vesicular monoamine transporter 2 (VMAT2) inhibitor to a subject in need thereof, wherein the subject has severe renal impairment.
APP
Utility
Methods for the Administration of Certain VMAT2 Inhibitors
18 Feb 21
Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-α-3-isobutyl-9,10-dimethoxy-1, 3,4, 6,7,11 b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is a CYP2D6 poor metabolizer.